AimwellBio FHIN — Enterprise Dashboard

ENTERPRISE / DEMO ENVIRONMENT · ENTERPRISE CLIENT TIER · ALL DATA IS ILLUSTRATIVE — NO LIVE API CONNECTIONS

AimwellBio Intelligence Platform

CLIENT Trial Signal Shield Command Growth Enterprise Alumni Partner FHIN Observer Contributor Researcher Institutional Community →

Positions Monitored

142

↑ 8 added this quarter

Capital Exposure

$4.2B

Across tracked positions

Active Signals (24h)

47

↑ 11 vs. trailing 24h

Adversarial Validations Running

12

3 awaiting decision

Network Depth

1,847

contributors · 32 regions

M&A Signals Tracked

29

↑ 4 this week

Signal Stream · Decision-Ready

Source-traced · Confidence-scored · Last 24h

FDA AdComm draft agenda flags PD-L1 subgroup endpoint inconsistency in oncology portfolio

REGULATORY Oncology Position: $480M exposure Source: FDA docket pre-read

Competitor Phase 2 readout shows superior PFS in cardiovascular indication you co-occupy

COMPETITIVE Cardiovascular Position: $620M exposure Source: ClinicalTrials.gov + press

EMA CHMP issues additional safety questions for biosimilar pathway — precedent affects two pipeline assets

REGULATORY Biologics 2 assets affected Source: EMA CHMP agenda

M&A signal: mid-cap diabetes specialist filed S-1 amendment — potential bolt-on to metabolic franchise

M&A Diabetes / Metabolic Source: SEC EDGAR

PubMed cluster: 7 new ccRCC papers cross-validate novel biomarker thesis your team flagged in Q1

RESEARCH Renal · ccRCC 7 citations Source: PubMed + BioRxiv

PMDA quietly updated wound-care device classification guidance — affects Japan launch sequencing

REGULATORY Wound Care Japan Source: PMDA bulletin

Novartis investor day commentary on neuroscience pipeline reorders your competitive map in rare-disease

COMPETITIVE Neurology · Rare Source: Investor transcript

Korean MFDS expanded indication review for GLP-1 class — affects three competing diabetes assets

REGULATORY Diabetes · GLP-1 Source: MFDS publication

Roche basket-trial protocol amendment hints at solid-tumor expansion strategy — flag for competitive review

COMPETITIVE Oncology · Solid Tumor Source: ClinicalTrials.gov diff

Twitter / X scientific KOL chatter elevated on ccRCC immunotherapy combinations — sentiment shift detected

MARKET Renal · ccRCC Source: KOL social signal

CMS draft NCD touches reimbursement pathway for wound-care biologics in your launch window

REGULATORY Wound Care · Reimbursement Source: CMS Federal Register

BioRxiv pre-print cluster on cardiovascular reverse-translation challenges a published Phase 3 mechanism

RESEARCH Cardiovascular 4 citations Source: BioRxiv pre-print

Adversarial Validation

SYNAPSE · ACTIVE

Should you proceed with oncology Phase 3 expansion ahead of FDA AdComm read-through?

ENT-SIG-2026-0524-001 · Initiated 14h ago

Proceed

9

Delay

14

Kill

3

Network consensus · current

DELAY · 54%

Dissenting factors flagged

PD-L1 subgroup endpoint inconsistency unresolved in two pivotal arms
FDA briefing-doc language suggests SAB pre-read concerns
Competitor Phase 2 readout reorders comparator assumptions
Two contributors flag historic precedent: 2023 Roche AdComm parallels

Portfolio Impact Heatmap

$ Exposure · By Severity

High

Med

Low

Info

Oncology

$480M

$210M

$85M

$40M

Cardiovascular

$620M

$140M

$60M

$25M

Diabetes / Metabolic

$180M

$320M

$110M

$55M

Renal / ccRCC

$95M

$220M

$140M

$30M

Wound / Rare

$70M

$160M

$90M

$45M

$ figures = aggregated tracked capital exposure

Account Team

Dedicated

MR

Marcus Reid

Senior Account Executive

corporate@aimwellbio.com
+1 (617) 555·0142

Next step · decision integrity

Initiate SYNAPSE adversarial validation on a position before the FDA, the board, or the market does it for you.

SYNAPSE convenes a structured network challenge across contributors, researchers, and institutional reviewers. Source-traced. Confidence-scored. PROCEED, DELAY, or KILL with the evidence to defend the call upstream.

1,847 CONTRIBUTORS · 32 REGIONS · ONE DECISION LAYER